UBS Group AG Cuts Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

UBS Group AG decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 35.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 935,479 shares of the company’s stock after selling 510,322 shares during the period. UBS Group AG’s holdings in Amneal Pharmaceuticals were worth $11,787,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in AMRX. Spire Wealth Management grew its position in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares during the last quarter. Comerica Bank grew its position in shares of Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after buying an additional 1,957 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $42,000. Advisory Services Network LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, Bellevue Group AG purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $79,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AMRX. Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. UBS Group began coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Seven research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Amneal Pharmaceuticals Trading Down 2.5%

NASDAQ:AMRX opened at $11.93 on Friday. The company has a market cap of $3.81 billion, a PE ratio of 31.40 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.02 and a twelve month high of $15.42. The company’s 50 day moving average is $12.65 and its two-hundred day moving average is $12.81.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The business had revenue of $722.52 million for the quarter. As a group, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 17.30% of the stock is owned by company insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.